What changed recently
Newly published and updated guidelines across every system, newest first. Each entry links to the official source.
173 older updates are outside this window. Show all time
- Reproductive & Women's HealthEU2026-07-07NICE guideline NG88 (March 2018) → NICE guideline NG88 (last updated July 2026)Uterine fibroids
The July 2026 update withdrew the recommendation on serum ferritin testing from the laboratory investigations section for women presenting with heavy menstrual bleeding. NG88 originally replaced the 2007 heavy menstrual bleeding guideline CG44.
- Gastrointestinal & HepatologyUS2026-07-012021 → 2026Diverticulitis
ACG replaced its 2021 diverticular disease guideline with a document focused on colonic diverticulitis, formalising selective rather than routine antibiotics for low-risk acute uncomplicated disease and listing the high-risk features (immunocompromise, frailty, unsafe outpatient care) that still warrant them. It also recommends against probiotics, mesalamine and rifaximin for recurrence prevention, drops nut/seed/popcorn avoidance, and limits post-recovery colonoscopy to complicated disease or patients with alarm features or overdue screening.
source ↗curation confidence 90% - Musculoskeletal & RheumatologyUS2026-06-242019 guideline → 2026 updateSpondyloarthritis
The 2026 revision of the 2019 adult guideline adds JAK inhibitors as a recommended option (a class absent from the previous version), keeps TNF and IL-17 inhibitors as the preferred first biologics, and advises against IL-23 inhibitors. It also broadens scope with new guidance on nociplastic pain, imaging strategy, bone health and comorbidities, and is accompanied by a first-ever companion guideline for juvenile axial spondyloarthritis.
- Musculoskeletal & RheumatologyEU2026-06-012022 update → 2025 updateRheumatoid arthritis
The task force consolidated the guidance from 11 recommendations down to 9 by merging and deleting items, while keeping methotrexate plus short-term glucocorticoids as the first step and adding a biologic DMARD after 3-6 months of inadequate response. Safety framing was sharpened, with JAK inhibitors requiring explicit assessment of cardiovascular and malignancy risk before use.
source ↗curation confidence 90% - Endocrine & MetabolicEU2026-05-132025 → 2026 updateObesity
Algorithm 2.0 refines the 2025 EASO framework using 62 randomised trials with evidence through 21 November 2025, sharpening the head-to-head comparisons of total body weight loss across available drugs. The liver domain was expanded beyond MASH resolution to include improvement in liver fibrosis as a treatment target.
- Renal & GenitourinaryUS2026-05-072021 guideline with 2023 amendment → 2026Benign prostatic hyperplasia
The AUA replaced its 2021 BPH/LUTS guideline and the targeted 2023 amendment with a full rebuild published in 2026, based on a fresh systematic literature review. The document was restructured into three parts covering presentation and evaluation, medical management, and procedural or surgical management.
source ↗curation confidence 90% - RespiratoryGLOBAL2026-05-012025 → 2026Asthma
The 2026 GINA report's headline addition is a set of four new flowcharts covering assessment, treatment and follow-up of acute asthma and exacerbations in adults, adolescents and children aged 6-11, in both primary and acute care settings. It also adds consensus guidance on which treatment step to start children aged 6-11 at, revised advice on biologics, oxygen saturation targets, SABA dosing and using ICS-formoterol instead of SABA for mild exacerbations, plus a stronger push to minimise oral corticosteroid exposure.
- Hematology & OncologyUS2026-04-162022 → 2022, amended 2026Prostate cancer
AUA amended the 2022 guideline after a literature review covering July 2021 to December 2024 (29 studies plus a set on artificial intelligence in disease management). The society describes the amendment as refining risk-based management, updating imaging and radiation therapy guidance, and strengthening the shared decision-making statements.
- Reproductive & Women's HealthEU2026-04-15NICE guideline NG23 (November 2024 update) → NICE guideline NG23 (updated November 2024; amended April 2026)Menopause
The April 2026 amendment reworked the advice on unscheduled vaginal bleeding while on systemic HRT, changing one recommendation and adding a new one so the guidance lines up with NICE's suspected cancer referral guidance. The preceding November 2024 update had added evidence-based recommendations on cognitive behavioural therapy for menopausal symptoms, on genitourinary symptoms, and on the health outcomes associated with HRT.
- Hematology & OncologyEU2026-04-142023 → 2026Colorectal cancer
ESMO replaced its 2023 metastatic colorectal cancer guideline with the 2026 edition (Cremolini et al., Ann Oncol 37(6):759-776); the 2023 document is now marked superseded in this atlas.
- Immunology & AllergyUS2026-04-012015 → 2025 practice parameterPrimary immunodeficiency
The 2025 parameter abandons the previous edition's structure of working through individual genetic entities and instead organises recommendations into a diagnosis part and a management part. Diagnosis now covers newborn screening for severe combined immunodeficiency, genetic testing and comorbidity surveillance, while management addresses immunoglobulin replacement, antibiotic prophylaxis, haematopoietic stem cell transplantation, precision medicine and quality-of-life assessment.
source ↗curation confidence 90% - Infectious DiseaseGLOBAL2026-04-012021 → 2026Sepsis & septic shock
The 2026 edition expands to 129 statements, 46 of them on questions the 2021 guidelines never addressed, including a conditional recommendation for point-of-care ultrasound to guide resuscitation and new guidance on active fluid removal once initial resuscitation is complete. Of the 38 questions carried over from 2021, only three recommendations actually reversed direction.
- Neurology & Special SensesUS2026-01-262019 Update → 2026Ischemic stroke
The 2026 guideline supersedes the 2018 guideline and its 2019 focused update, placing tenecteplase 0.25 mg/kg on equal footing with alteplase inside the 4.5-hour window, allowing imaging-selected thrombolysis out to roughly 9 hours, widening thrombectomy eligibility to include basilar occlusions and large ischaemic cores, endorsing mobile stroke units and refined EMS triage, and adding the first AHA/ASA recommendations for paediatric acute ischaemic stroke.
- Endocrine & MetabolicUS2026-01-012025 → 2026Diabetes complications
The 2026 edition added a new pathophysiology introduction drawing on 40-year DCCT/EDIC follow-up, discussed the eye effects of GLP-1 receptor agonists including NAION and retinopathy progression, added the Ipswich touch test to neuropathy assessment, and revised Rec 12.22 to stress combination therapy for neuropathic pain. Foot care sections now cover home foot-temperature monitoring, expanded WIfI staging, and emerging evidence that GLP-1 RAs may cut lower-extremity amputations.
- Endocrine & MetabolicUS2026-01-012025 → 2026Type 2 diabetes
The 2026 edition added a recommendation to use a dual GIP/GLP-1 receptor agonist in type 2 diabetes with symptomatic heart failure with preserved ejection fraction, and reworked the MASLD/MASH guidance so a GLP-1 RA with proven hepatic benefit is preferred, with pioglitazone or a dual GIP/GLP-1 RA as alternatives. Guidance on continuing GLP-1-based therapy in advanced chronic kidney disease was also expanded.
- Endocrine & MetabolicUS2026-01-012025 → 2026Type 1 diabetes
For insulin-treated diabetes the 2026 edition broadened continuous glucose monitoring to be offered at diagnosis and at any later point (Rec 9.25), and strengthened the recommendation that automated insulin delivery systems be offered to eligible adults. A new recommendation also addresses screening for insulin need and ketoacidosis risk in immune checkpoint inhibitor-associated diabetes.
- DermatologyEU2026-01-012018 EDF atopic eczema guideline → Living guideline, January 2026 updateAtopic dermatitis
The January 2026 update to the living EuroGuiDerm atopic eczema guideline re-voted the systemic treatment chapters and redrew the treatment algorithms for adults and for children and adolescents. Azathioprine and alitretinoin recommendations were withdrawn, mycophenolate and omalizumab were moved to past therapies, and new guidance was added on vaccination, switching between drugs, dose interval adjustment, and pregnancy and breastfeeding.
source ↗curation confidence 90% - DermatologyEU2026-01-012016 European evidence-based (S3) guideline → Update 2025Acne
The EuroGuiDerm update revises the 2016 European S3 acne guideline around three priority questions: when to choose isotretinoin over systemic antibiotics, how long antibiotics should run and when to use hormonal therapy or spironolactone, and how to position the newer topicals trifarotene and clascoterone. It also revises advice on benzoyl peroxide safety, choice of systemic antibiotic, treatment in pregnancy and isotretinoin dosing, leaving the rest of the 2016 text in place.
source ↗curation confidence 90% - Renal & GenitourinaryEU2026-01-012025 → 2026Urinary tract infection
The 2026 EAU urological infections guideline is a limited update of the 2025 edition adding 36 studies across two sections. It revises the diagnostic and antimicrobial treatment recommendations for cystitis, updates antibiotic dosages throughout, strengthens periprocedural antibiotic prophylaxis guidance for prostate biopsy, and adds a new section on the diagnosis and treatment of fungal urinary tract infections.
- Renal & GenitourinaryEU2026-01-012025 → 2026Nephrolithiasis
The 2026 EAU urolithiasis guideline is a full update of the 2025 edition incorporating 126 newly identified studies, with revised recommendations on renal colic management, medical expulsive therapy, antibiotic prophylaxis for shock wave lithotripsy, retrograde and antegrade ureteroscopy, percutaneous nephrolithotomy, management of antithrombotic therapy around stone treatment, and radiation protection in endourology.
- Renal & GenitourinaryEU2026-01-012025 → 2026Benign prostatic hyperplasia
The 2026 EAU male LUTS guideline is a full revision of the 2025 edition: it adds a new section on prostate cancer within the diagnostic chapter, changes the strength rating for beta-3 agonists in conservative treatment, expands the surgical chapter with two new subsections emphasising alternative enucleation and ablative techniques, and adds guidance on male urinary incontinence, detrusor underactivity and voiding dysfunction in younger men.
- Dental & Oral HealthUS2026-01-012017 guideline → Living guideline, 2026 updateOral cancer
The 2026 living guideline updates the ADA's 2017 statement on potentially malignant oral disorders and now conditionally recommends against vital staining adjuncts such as toluidine blue for deciding on biopsy or referral, warning they can prompt unnecessary procedures or delay diagnosis. Conventional visual and tactile examination plus scalpel or punch biopsy with histopathology is reaffirmed as the standard pathway.
- Hematology & OncologyEU2026-01-012025 → 2026 editionProstate cancer
The EAU panel describes the 2026 text as a limited update of the 2025 publication, with revised evidence summaries and recommendations for MRI in biopsy indication and strategy, for staging, and for active surveillance strategy, plus an adapted EAU risk-group table for localised and locally advanced disease.
- Hematology & OncologyUS2026-01-012026.1.0 → 2026.1.1Multiple myeloma
This living-guideline version bump revisits the evidence base from a February 2026 literature search and issues updated recommendations covering the teclistamab plus daratumumab combination; the preceding 2026.1.0 release had itself replaced the 2019 guideline by adding first-ever guidance on smoldering myeloma and incorporating CAR T-cell, bispecific antibody and antibody-drug conjugate options.
source ↗curation confidence 90% - Endocrine & MetabolicUS2025-12-092016 → 2025 UpdateObesity
The 2025 update to AACE's 2016 obesity guidance moved diagnosis away from BMI alone toward adiposity-based criteria and complication-driven staging, and reframed treatment success around metabolic health and complication resolution rather than weight loss percentage. It also added explicit hierarchies of preferred medications matched to each obesity-related complication, reflecting the arrival of highly effective incretin-based agents.
source ↗curation confidence 90% - Immunology & AllergyEU2025-12-012016 revision → ARIA-EAACI 2024-2025 revision, Part IAllergic rhinitis
This ARIA revision rebuilds the intranasal treatment recommendations around eleven prioritised questions using the GRADE evidence-to-decision framework, drawing on mHealth and pharmacovigilance data and an expert cost survey alongside systematic reviews. It now suggests a fixed combination of intranasal antihistamine plus intranasal corticosteroid ahead of either agent alone, and intranasal corticosteroid ahead of intranasal antihistamine when a single agent is used.
source ↗curation confidence 80% - Hematology & OncologyUS2025-12-012020 → 2025 updateLeukemia
The 2025 ASH panel retired the 2020 guideline's split between "intensive" and "non-intensive" therapy, framing recommendations instead around candidacy for antileukaemic therapy, and it now positions venetoclax-based combinations alongside conventional induction and post-remission therapy for older adults with newly diagnosed AML.
source ↗curation confidence 90% - Renal & GenitourinaryUS2025-11-202016 → 2025Nephrolithiasis
The AUA replaced its 2016 surgical stone guideline with a new edition released in November 2025, developed from a GRADE-based review of literature published between 2000 and 2025. It is issued as a three-part series spanning evaluation, treatment and future directions, and covers shock wave lithotripsy, ureteroscopy and both standard and mini percutaneous nephrolithotomy.
source ↗curation confidence 90% - RespiratoryGLOBAL2025-11-102025 → 2026COPD
The 2026 GOLD report widens the 'exacerbator' label so a single moderate or severe exacerbation in the past year now counts (previously two or more were needed), reframes the ABE assessment around disease activity, stability and control, revises the exacerbation-severity classification, and positions high-flow nasal therapy as a first-line respiratory support option in exacerbations. A new chapter on emerging technology and artificial intelligence in COPD was also added.
- Gastrointestinal & HepatologyUS2025-11-012018 → 2025 updateHepatitis B
The 2025 AASLD/IDSA guideline tackles six GRADE-based questions the 2018 guidance left unresolved, including whether to treat HBsAg-positive people in the immune-tolerant and indeterminate phases, when to withdraw antiviral therapy, and HCC surveillance in HBV coinfection and after HBsAg loss. Recommendations from 2018 that were not revisited remain in force, and an integrated algorithm combines old and new guidance.
source ↗curation confidence 90% - Emergency & Critical CareUS2025-10-222020 → 2025Cardiac arrest & ACLS
The 2025 edition replaces the four separate 2020 Chains of Survival with a single unified six-link chain spanning adult, paediatric and in-hospital arrest, and adds first-time guidance for choking in responsive adults using alternating back blows and abdominal thrusts. It also advises against routine mechanical CPR devices, reserving them for situations where manual compressions are unsafe or impractical, and extends delayed cord clamping in newborns to at least 60 seconds.
- Infectious DiseaseUS2025-10-142023 guideline → Living guideline, updated October 2025COVID-19
The October 2025 antiviral update reframed treatment decisions around preventing hospitalisation rather than death, given higher population immunity. It keeps a strong recommendation for nirmatrelvir/ritonavir in adults at high risk of progression but now suggests against routine antiviral treatment in mild to moderate COVID-19 without risk factors.
source ↗curation confidence 80% - Infectious DiseaseEU2025-10-0112.1 → 13.0HIV
Version 13.0 restructured the guidelines into two parts, added a new consolidated Substance Use section covering alcohol, opioid use and chemsex, and extensively rewrote the obesity guidance to cover pharmacotherapy and bariatric surgery. Recommended first-line ART regimens for treatment-naive adults were left unchanged from v12.1, and the lipodystrophy section was retired.
- Hematology & OncologyUS2025-10-012.2025 → 3.2025Lymphoma
NCCN's published Insights article for this version bump describes the panel's discussion of newly incorporated data in three areas: CD3xCD20 bispecific antibodies and CD19-directed antibodies/antibody-drug conjugates in relapsed or refractory follicular lymphoma, BTK inhibitor-based regimens in TP53-mutated classical mantle cell lymphoma, and bispecific antibodies added to chemoimmunotherapy in relapsed or refractory DLBCL.
source ↗curation confidence 90% - Infectious DiseaseUS2025-09-25September 12, 2024 update → Living guideline, updated September 2025HIV
The September 2025 revision added a dedicated chapter on cardiovascular and metabolic complications as people with HIV approach normal life expectancy, and retired the standalone statin primary-prevention section in favour of the ACC/AHA multisociety dyslipidaemia guidance. It also revised laboratory monitoring intervals, added subsections on starting ART in early infection and in hospitalised patients, and expanded cost guidance around long-acting injectables.
source ↗curation confidence 90% - Neurology & Special SensesEU2025-09-085th Edition → 6th EditionGlaucoma
The 6th edition refreshes the evidence-based chapter with a new set of clinical questions and GRADE-style answers, and substantially rewrites the 'what matters to patients' material using direct input from patient advisors in the EGS Patient Involvement Project, including eight practical communication tips for clinicians.
source ↗curation confidence 90%